A brief history of Tomorrow.bio

When people hear that Tomorrow.bio was founded in 2020, the first reaction is sometimes surprise.

It sounds recent for an organisation asking to be trusted with a responsibility that may last for centuries.

I understand that reaction. In most industries, six years is not a long history. In cryopreservation, however, the useful question is not simply how many birthdays an organisation has had.

The useful question is: what did it build with that time?

Tomorrow.bio did not start as a website selling a future service. We started by building the medical capability, legal structure and physical infrastructure needed to perform cryopreservation in Europe.

Then we had to prove that the whole system could work in real cases.

This is that story.

The foundation came first

The story begins before Tomorrow.bio itself.

On 27 May 2019, six founders established the European Biostasis Foundation in Switzerland. They chose a nonprofit foundation because research and patient care require a much longer horizon than an ordinary company.

Tomorrow Biostasis GmbH followed in Berlin in January 2020. It was founded by Emil Kendziorra and Fernando Azevedo Pinheiro, bringing together medicine, engineering, operations and entrepreneurship.

We had a simple problem to solve.

Cryopreservation existed, but a person living in Europe still lacked a modern provider built around fast local response, professional medical operations and long-term storage close to home.

Honestly, the easier route would have been to talk about the idea for a few years first.

We did the opposite.

The first members joined in March 2020. By June, our first perfusion system was operational. In November, our first dedicated biostasis ambulance entered service.

Those dates were close together because we did not want to collect members for a service that existed only on a slide deck.

We wanted the equipment, protocols and response capability to exist from the beginning.

The early team was small. Everyone did several jobs, because there was no standard job description for building a cryopreservation organisation in Europe.

Medical procedures, vehicle design, member support, logistics and public communication all had to grow at the same time.

That hands-on culture still matters. Cryopreservation does not improve through branding. It improves when people train, test equipment, review data and correct what did not work.

Building the place where patients would stay

An ambulance can reach a patient. It cannot care for that patient for the next hundred years.

That required a second kind of organisation and a very different type of infrastructure.

In February 2021, EBF acquired the property for its facility in Rafz, Switzerland. Construction took about a year and a half, and the building was handed over in March 2022.

This was not a rented warehouse with a cryogenic vessel placed inside.

EBF owns both the plot and the building. The facility includes medical, imaging, laboratory, storage and operational space, with the storage area protected inside its underground structure.

The first cryogenic storage dewar arrived in June 2022. The facility has been operational since that year.

Since then, EBF has expanded capacity, installed automated liquid-nitrogen refilling, improved handling systems and developed cryogenic imaging and quality-control capabilities.

You can read the engineering detail in the long-term storage facility. The important historical point is simpler.

By 2022, Tomorrow.bio members no longer had to imagine where long-term care might eventually happen. The facility was there, in Switzerland, operating.

We did not build a company first and promise to solve long-term care later. Long-term care was part of the structure from the beginning.

The organisational design continued to mature.

In April 2024, the Patient Care Foundation was established in Switzerland. It acts as the legal guardian of patients' bodies and dedicated capital, while EBF owns and operates the facility.

Tomorrow.bio remains the operating company. It serves members, maintains standby capability and performs cryopreservation procedures.

Three organisations may sound more complicated than one. It is.

But the complication has a purpose. The company that must move quickly and take operating risks does not control long-term patient capital or own the patients in care.

The Tomorrow.bio ecosystem explains how those responsibilities connect.

The first real cases changed everything

Until 2023, Tomorrow.bio had members, trained teams, ambulances, equipment and a completed facility.

It still had not performed a human cryopreservation.

Our first human case took place in March 2023. The first pet case followed in August. A second ambulance joined the operation in October.

In April 2024, we completed our first brain-only cryopreservation. By June, membership had reached 600. In July, Tomorrow.bio launched in the continental United States.

Real cases changed the organisation in a way no simulation could.

A training scenario begins on time. A real emergency does not.

Hospitals, families, funeral partners, airlines, authorities and weather do not arrange themselves around the protocol. The team has to make the protocol work around reality without sacrificing the quality of the procedure.

This is why we publish cryopreservation case reports. The reports do not present every case as perfect. They show timings, measurements, complications and the actual sequence of events.

That record now includes reports from cases completed in 2025, not only the first cases from 2023 and 2024.

We also began using CT imaging to assess every human cryopreservation, turning internal quality questions into measurements that can be compared and improved.

The broader system is described in biostasis quality checks. This is where Tomorrow.bio's history becomes more than a sequence of dates.

Every case should make the next one better.

Growth is useful when it builds capability

By the end of 2022, Tomorrow.bio had 250 members. It reached 600 in June 2024 and more than 1,000 members by 2026.

As of 8 July 2026, Tomorrow.bio reported more than 1,010 members across over 200 cities and 45 countries.

Those numbers make us proud. They are not trophies.

Growth pays for teams, ambulances, training, equipment, research and a denser response network. It gives us more operational experience and more data with which to improve preservation quality.

This is why we care about scale.

Our member interviews also made something else clear. For many people, the existence of a credible European provider was itself the missing piece.

Some had known about cryonics for years. They acted when they saw a real facility, a working team, published cases or simply received a clear answer from a human being.

That is not a technical milestone, but it belongs in the history.

Trust was built through things people could inspect and people they could speak to. Not through a promise that we had solved death.

We have not solved it.

No human cryopreserved by any organisation has been revived, and nobody can honestly give a probability or date for when that may become possible.

But this uncertainty is exactly why present-day execution matters so much. There is no future chance to benefit from better medicine if the information needed for recovery is badly preserved today.

Tomorrow.bio was created to improve that first, decisive part of the problem.

Since 2020, we have moved from one perfusion system and one ambulance to an operation spanning Europe and the continental United States, supported by a purpose-built Swiss facility and two foundations dedicated to research and patient care.

We are still early in the mission. We are not early in operating it.

That is the point of this history.

Tomorrow.bio is no longer an argument for what a European cryopreservation organisation could look like. It is a working organisation, built case by case, and still improving.

Further reading

• The founders
• Building organisations meant to last
• What happens if Tomorrow.bio fails?
• How standby, stabilisation and transport work